MCID: ORL006
MIFTS: 22

Oral Mucosa Leukoplakia

Categories: Oral diseases

Aliases & Classifications for Oral Mucosa Leukoplakia

MalaCards integrated aliases for Oral Mucosa Leukoplakia:

Name: Oral Mucosa Leukoplakia 12 15
Leukoplakia of Buccal Mucosa 70
Leukoplakia, Oral 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9655
ICD9CM 34 528.6
ICD10 32 K13.21
UMLS 70 C0023532 C0399470 C1112530

Summaries for Oral Mucosa Leukoplakia

Disease Ontology : 12 A mouth disease that is characterized by a white patch or plaque that develops in the oral cavity and is strongly associated with smoking.

MalaCards based summary : Oral Mucosa Leukoplakia, also known as leukoplakia of buccal mucosa, is related to leukoplakia and lichen planus. An important gene associated with Oral Mucosa Leukoplakia is GSTP1 (Glutathione S-Transferase Pi 1). The drugs Rosiglitazone and Celecoxib have been mentioned in the context of this disorder. Related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Oral Mucosa Leukoplakia

Diseases related to Oral Mucosa Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukoplakia 10.2
2 lichen planus 10.0
3 oral leukoplakia 10.0

Symptoms & Phenotypes for Oral Mucosa Leukoplakia

GenomeRNAi Phenotypes related to Oral Mucosa Leukoplakia according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 9.36 GSTP1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.36 G3BP1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 9.36 G3BP1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-133 9.36 GSTP1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 9.36 G3BP1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 9.36 GSTP1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.36 GSTP1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.36 G3BP1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.36 GSTP1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.36 G3BP1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-9 9.36 GSTP1

Drugs & Therapeutics for Oral Mucosa Leukoplakia

Drugs for Oral Mucosa Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
2
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
3
Pembrolizumab Approved Phase 2 1374853-91-4
4
nivolumab Approved Phase 2 946414-94-4
5
Metformin Approved Phase 2 657-24-9 4091 14219
6
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
7
Maleic acid Experimental Phase 2 110-16-7 444266
8 Analgesics, Non-Narcotic Phase 2
9 Cyclooxygenase Inhibitors Phase 2
10 Antirheumatic Agents Phase 2
11 Anti-Inflammatory Agents Phase 2
12 Analgesics Phase 2
13 Anti-Inflammatory Agents, Non-Steroidal Phase 2
14 Cyclooxygenase 2 Inhibitors Phase 2
15 Antineoplastic Agents, Immunological Phase 2
16 Tea Phase 2
17 Hypoglycemic Agents Phase 2
18
Erythromycin Approved, Investigational, Vet_approved Phase 1 114-07-8 12560
19
Isotretinoin Approved Phase 1 4759-48-2 5282379 5538
20
Aminolevulinic acid Approved Phase 1 106-60-5 137
21 Erythromycin stearate Phase 1
22 Erythromycin Estolate Phase 1
23 Erythromycin Ethylsuccinate Phase 1
24 Photosensitizing Agents Phase 1
25 Dermatologic Agents Phase 1
26
Sulindac Approved, Investigational 38194-50-2 5352 1548887
27
Heparin Approved, Investigational 9005-49-6 772 9812414
28
Fluconazole Approved, Investigational 86386-73-4 3365
29
Clotrimazole Approved, Vet_approved 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
31
Nitric Oxide Approved 10102-43-9 145068
32
Nitrous oxide Approved, Vet_approved 10024-97-2 948
33
Ethanol Approved 64-17-5 702
34
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
35 Hemostatics
36 Coagulants
37 Tolonium Chloride
38 calcium heparin
39 Cytochrome P-450 Enzyme Inhibitors
40 Hormone Antagonists
41 Hormones
42 Anti-Infective Agents
43 Antifungal Agents
44 Pharmaceutical Solutions
45 Protective Agents
46 Antioxidants

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia Completed NCT00099021 Phase 2 pioglitazone hydrochloride
3 Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
4 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
5 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
6 A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia Recruiting NCT03603223 Phase 2
7 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Recruiting NCT03692325 Phase 2 Nivolumab
8 M4OC-Prevent: Metformin for Oral Cancer Prevention Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
9 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2 Lozenge Intake
10 Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study Terminated NCT00951379 Phase 2 Pioglitazone hydrochloride
11 A Phase 1, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of SBS-101 After Intraoral Application in Patients With Oral Premalignant Lesions (OPL) Not yet recruiting NCT03939364 Phase 1 SBS-101;Placebo
12 Phase I Study of Photodynamic Therapy Using Pulsed Dye Laser and Oral Aminolevulinic Acid in Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1 aminolevulinic acid hydrochloride;photodynamic therapy
13 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
14 A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions Completed NCT00299195 sulindac;Placebo
15 Efficacy of Rose Bengal in Comparison With Toluidine Blue in Detection of Premalignant Lesions: a Preliminary Study Completed NCT03031899
16 Association of Candida and Antifungal Therapy With Pro-inflammatory Cytokines in Oral Leukoplakia- A Pilot Study Completed NCT04712929
17 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Completed NCT03682562
18 Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia Completed NCT03233165
19 Development of an Oral Epithelial Dysplasia Informational Needs Questionnaire Completed NCT04153266
20 Malondialdehyde and Nitrous Oxide as Salivary Biomarkers for Different Oral Lesions Completed NCT04267419
21 Prospective Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore Recruiting NCT03975322
22 Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia: A Randomized Placebo Controlled Study Recruiting NCT04251845
23 Dental Hygienists and Oral Mucosal Inspection - Extent, Knowledge and Perceived Barriers Recruiting NCT04079491
24 Biomarkers for Oral Cancer Active, not recruiting NCT00341497
25 Clinical Evaluation of the OncAlert RAPID; Impact on Decision-Making Active, not recruiting NCT03239834
26 Fluorescence &Amp; Reflectance Imaging to Detect Oral Neoplasia Active, not recruiting NCT00542373
27 Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions Not yet recruiting NCT04732741
28 THE HONG KONG ORAL CANCER EDUCATION AND SCREENING (HOCES) PROGRAM: REFINING DISEASE PREVENTION, RISK STRATIFICATION AND EARLY DETECTION Not yet recruiting NCT04487938

Search NIH Clinical Center for Oral Mucosa Leukoplakia

Genetic Tests for Oral Mucosa Leukoplakia

Anatomical Context for Oral Mucosa Leukoplakia

Publications for Oral Mucosa Leukoplakia

Articles related to Oral Mucosa Leukoplakia:

(show top 50) (show all 103)
# Title Authors PMID Year
1
Molecular and Immunohistochemical Cognizance of HPV16 in Oral Leukoplakia, Oral Squamous Cell Carcinoma and Oropharyngeal Squamous Cell Carcinoma. 61
33646558 2021
2
Malignant transformation of oral leukoplakia: Systematic review and meta-analysis of the last 5 years. 61
33606345 2021
3
[Oral leukoplakia associated with Human Papilloma Virus; a bipolar infection in a young patient]. 61
33351365 2020
4
Salivary bacterial shifts in oral leukoplakia resemble the dysbiotic oral cancer bacteriome. 61
33391629 2020
5
Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. 61
33128420 2020
6
Evaluation of serum immunoglobulin (IgG, IgM, IgA) in potentially malignant disorders of oral cavity - A case control study. 61
33005564 2020
7
Correlation Between Histological Grading and Ploidy Status in Oral Leukoplakia, Oral Submucous Fibrosis, and Oral Squamous Cell Carcinoma: A Flow Cytometric Analysis. 61
33149437 2020
8
Comparative evaluation of survivin expression in leukoplakia, lichen planus, and oral squamous cell carcinoma: An immunohistochemical study. 61
32719269 2020
9
[Modern perspectives of oral squamous cell carcinoma]. 61
32593268 2020
10
WNT signalling pathway in oral lesions. 61
31740880 2019
11
Serum fucose level in oral cancer, leukoplakia, and oral sub mucous fibrosis: A biochemical study. 61
31463268 2019
12
Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe vera, Green Tea and Coffee Properties. 61
30884918 2019
13
Oxidative Stress and Oral Mucosal Diseases: An Overview. 61
30804105 2019
14
Photodynamic therapy in the treatment of oral leukoplakia: A systematic review. 61
30391342 2019
15
Insight into verruciform xanthoma with oral submucous fibrosis: Case report and review of literature. 61
30967723 2019
16
Evaluation of Serum C-Reactive Protein Levels in Oral Premalignancies and Malignancies: A Comparative Study. 61
30842796 2018
17
Evaluation of mast cells in oral premalignant and malignant lesions: A histochemical study. 61
30546233 2018
18
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry 61
29699065 2018
19
Evaluating the Role of Immunological Cells (Tissue Eosinophils and Mast Cells) in Progression of Oral Squamous Cell Carcinoma. 61
29769506 2018
20
"Omics" in oral cancer: New approaches for biomarker discovery. 61
29247855 2018
21
[Diagnostic value of optical coherence tomography for oral leukoplakia assessment]. 61
29465074 2018
22
Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma. 61
29410757 2017
23
Qualitative analysis of the impact of Oral Potentially Malignant Disorders on daily life activities. 61
28410381 2017
24
Analysis of silver binding nucleolar organizer regions in exfoliative cytology smears of potentially malignant and malignant oral lesions. 61
28296547 2017
25
Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma. 61
27849339 2016
26
Immunohistochemical Evaluation of Mast Cells in Leukoplakia and Oral Squamous Cell Carcinoma. 61
27656549 2016
27
GSTM1 null polymorphism prevalence in tobacco users, oral leukoplakia and oral squamous cell carcinoma patients in South Indian population: A polymerase chain reaction study. 61
27723629 2016
28
In vivo confocal microscopy for the oral cavity: Current state of the field and future potential. 61
26786962 2016
29
Salivary 8-hydroxy-2-deoxyguanosine, malondialdehyde, vitamin C, and vitamin E in oral pre-cancer and cancer: diagnostic value and free radical mechanism of action. 61
26077895 2016
30
[Determination of human papillomavirus in oral leukoplakia,oral lichen planus and oral squamous cell carcinoma]. 61
26885914 2016
31
Current strategies for prevention of oral manifestations of human immunodeficiency virus. 61
26679357 2016
32
Potentially malignant oral lesions: clinicopathological correlations. 61
27074232 2016
33
Exophytic Verrucous Hyperplasia of the Oral Cavity – Application of Standardized Criteria for Diagnosis from a Consensus Report 61
27865210 2016
34
A new approach to exfoliative cytology: A comparative cytomorphometric study. 61
27146777 2016
35
Metabolic syndrome and health-related behaviours associated with pre-oral cancerous lesions among adults aged 20-80 years in Yunlin County, Taiwan: a cross-sectional study. 61
26685025 2015
36
Oral lesions, chronic diseases and the risk of head and neck cancer. 61
26526128 2015
37
Morphometry As a Diagnostic Tool for Potentially Malignant Lesions. 61
26816987 2015
38
Evaluation of stromal myofibroblasts in oral leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma--an immunohistochemical study. 61
26881537 2015
39
Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. 61
26159805 2015
40
Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis. 61
26339574 2015
41
A histochemical comparison of methyl green-pyronin, and hematoxylin and eosin for detecting apoptotic cells in oral squamous cell carcinoma, oral leukoplakia, oral submucous fibrosis and normal oral mucosa. 61
25539051 2015
42
Prevalence of glutathione S-transferase M1 null polymorphism in tobacco users, oral leukoplakia and oral squamous cell carcinoma patients in South Indian population: A polymerase chain reaction study. 61
25821378 2015
43
The association between miR-499a polymorphism and oral squamous cell carcinoma progression. 61
24690080 2015
44
Comparison of Immunohistochemical Expression of Antiapoptotic Protein Survivin in Normal Oral Mucosa, Oral Leukoplakia, and Oral Squamous Cell Carcinoma. 61
26457223 2015
45
Cytomorphometric analysis of oral submucous fibrosis and leukoplakia using methyl green-pyronin Y, Feulgen staining and exfoliative brush cytology. 61
24867495 2015
46
The master switch: Comparative study of mast cell in oral epithelial dysplasia, oral submucous fibrosis and oral squamous cells carcinoma and their association with inflammation and angiogenesis. 61
26097302 2015
47
Status of trace elements in saliva of oral precancer and oral cancer patients. 61
25879353 2015
48
Role of Lycopene in Preventing Oral Diseases as a Nonsurgical Aid of Treatment. 61
26330986 2015
49
Mast cells and oral pathologies: A Review. 61
25810632 2015
50
Precancerous lesions of oral mucosa. 61
25516862 2014

Variations for Oral Mucosa Leukoplakia

Expression for Oral Mucosa Leukoplakia

Search GEO for disease gene expression data for Oral Mucosa Leukoplakia.

Pathways for Oral Mucosa Leukoplakia

GO Terms for Oral Mucosa Leukoplakia

Sources for Oral Mucosa Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....